H

Holdsworth House Medical Practice | Sydney, Australia

Research site
(Unclaimed)
Location
Level 3, 26 College Street DarlinghurStreet, Sydney, New South Wales, Australia

Site insights

Top conditions

Top treatments

Raltegravir
Atazanavir
LY3298176
Metformin
Ritonavir
Tirzepatide
LY3041658
Spesolimab
THC
ZGN-1061

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 43 total trials

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Eltrekibart
Drug: Placebo

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo Nodularis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in...

Active, not recruiting
Osteoarthritis, Knee
Biological: PTP-001
Other: Placebo control

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 2

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling
HIV-1-infection
Drug: Bictegravir
Drug: BIC/LEN FDC

Prospective clinical pilot study for subjects diagnosed with Occupational Progressive Pneumoconiosis.Subjects will be treated with Nintedanib 150mg t...

Enrolling
Silicosis
Pneumoconiosis Coal
Drug: Nintedanib 150 MG [Ofev]

Trial sponsors

K
Lilly logo
Amgen logo
Gilead Sciences logo
H
Boehringer Ingelheim logo
Pfizer logo
A
Bayer logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems